Learning from IO-IO combo misses
In the frantic rush to the clinic with various IO-IO combinations, many people seem to have forgotten that these have an increased risk of failure than say, combining one IO molecule with chemotherapy.
This risk can take the form of increased toxicities, as well as lack of efficacy, especially if you are giving an unknown therapy instead of one that is known to be effective in controlling the tumour.
We look at a tale of two cities in lung cancer; there are some interesting lessons to be learned here…
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
